Key facts
- This page summarizes Phillip A. Sharp's Form 4 filing for ALNYLAM PHARMACEUTICALS, INC. (ALNY).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 24 Jan 2025, 16:10.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 2, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025.
Footnote F2
Includes shares held by the Phillip A. Sharp Revocable Trust, of which the reporting person and his spouse are co-trustees. Also includes shares held in trust for the benefit of the reporting persons children, of which the reporting persons children and spouse are the trustees.
Footnote F3
This stock option was fully vested and exercisable as of June 1, 2016.